For patients with HRRm prostate cancer receiving Akeega and Zytiga with prednisone, quality of life remained at baseline.

“You can see that there was an initial reduction in the HR-QOL score in the niraparib arm, which may have been explained by the onset of the most frequently observed adverse events, which included ...

A new drug combination could significantly delay the progression of a life-threatening form of prostate cancer in men with ...

Amplitude CEO Spenser Skates tells CNBC he expects a significant correction in the artificial intelligence sector, warning ...

Rathkopf presented the Late-breaking abstract 91 - Patient-reported outcomes (PROs) from AMPLITUDE, a randomized placebo-controlled phase 3 trial of niraparib (NIRA) and abiraterone acetate (AA) plus ...

The CEO of Amplitude is glad that his company went public in 2021, despite a sharp contraction in the value of tech shares since its IPO. In a wide-ranging conversation on TechCrunch’s Equity Podcast, ...

Amplitude (AMPL) saw its shares slip 4% at the last close, reflecting recent volatility for the digital analytics provider. With shares down 10% over the past month, investors are watching for signals ...

Long before your lounge room became an increasingly cluttered stage space for plastic instruments there was Amplitude, Harmonix’s second stab at rhythm-action that would help lay the foundation for a ...

Amplitude Energy ( ($AU:AEL) ) just unveiled an update. Amplitude Energy Limited announced the quotation of 79,728,878 ordinary fully paid ...